ATE366110T1 - Verwendung von inhibitoren des renin-angiotensin systems - Google Patents

Verwendung von inhibitoren des renin-angiotensin systems

Info

Publication number
ATE366110T1
ATE366110T1 AT04021889T AT04021889T ATE366110T1 AT E366110 T1 ATE366110 T1 AT E366110T1 AT 04021889 T AT04021889 T AT 04021889T AT 04021889 T AT04021889 T AT 04021889T AT E366110 T1 ATE366110 T1 AT E366110T1
Authority
AT
Austria
Prior art keywords
renin
angiotensin system
system inhibitors
inhibitors
angiotensin
Prior art date
Application number
AT04021889T
Other languages
English (en)
Inventor
Hugh Edward Montgomery
John Francis Martin
Jorge Daniel Erusalimsky
Original Assignee
Ark Therapeutics Ltd
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26312447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366110(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9722026.3A external-priority patent/GB9722026D0/en
Priority claimed from GBGB9810855.8A external-priority patent/GB9810855D0/en
Application filed by Ark Therapeutics Ltd, Boehringer Ingelheim Int filed Critical Ark Therapeutics Ltd
Application granted granted Critical
Publication of ATE366110T1 publication Critical patent/ATE366110T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/02—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
    • C08G61/04—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
    • C08G61/06—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds
    • C08G61/08—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
AT04021889T 1997-10-17 1998-10-19 Verwendung von inhibitoren des renin-angiotensin systems ATE366110T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9722026.3A GB9722026D0 (en) 1997-10-17 1997-10-17 Use of compounds
GBGB9810855.8A GB9810855D0 (en) 1998-05-20 1998-05-20 Use of compounds

Publications (1)

Publication Number Publication Date
ATE366110T1 true ATE366110T1 (de) 2007-07-15

Family

ID=26312447

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98947698T ATE294579T1 (de) 1997-10-17 1998-10-19 Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
AT04021889T ATE366110T1 (de) 1997-10-17 1998-10-19 Verwendung von inhibitoren des renin-angiotensin systems

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98947698T ATE294579T1 (de) 1997-10-17 1998-10-19 Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel

Country Status (19)

Country Link
US (7) US7071183B2 (de)
EP (4) EP1776954A3 (de)
JP (2) JP5187991B2 (de)
KR (3) KR100572080B1 (de)
CN (1) CN1123342C (de)
AP (1) AP1300A (de)
AT (2) ATE294579T1 (de)
AU (1) AU742506B2 (de)
CA (2) CA2306216C (de)
CY (1) CY1106813T1 (de)
DE (2) DE69830069T3 (de)
DK (2) DK1498124T3 (de)
ES (2) ES2287617T3 (de)
HU (2) HU0900792D0 (de)
NO (1) NO326231B1 (de)
PL (2) PL197164B1 (de)
PT (2) PT1498124E (de)
UY (2) UY25971A1 (de)
WO (1) WO1999020260A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU2001246864B2 (en) * 2000-04-10 2006-07-27 Protein Express Co., Ltd. Hypotensors
WO2002099098A1 (en) * 2001-04-04 2002-12-12 American Diagnostica, Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
GB0119460D0 (en) * 2001-08-09 2001-10-03 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
AU2002364381A1 (en) * 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
EP1382334A1 (de) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Verwendung von Angiotensin II AT1-Rezeptorblockern, allein oder in Kombination mit Thiazide oder Angiotensin II zur Behandlung von Schlaganfall
EP2204455A1 (de) 2002-08-29 2010-07-07 American Diagnostica, Inc. Diagnostischer Assay für den mit Thrombin aktivierbaren Fibrinolyse-Inhibitor (TAFI)
EP1600166A4 (de) * 2003-01-17 2008-02-27 Takeda Pharmaceutical Skelettmuskelschutzmittel
WO2005084648A1 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising candesartan cilexetil
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006009325A1 (ja) * 2004-07-23 2006-01-26 Ono Pharmaceutical Co., Ltd. メタロプロテアーゼ阻害剤
EP1990049A3 (de) * 2005-03-21 2008-11-26 Vicus Therapeutics SPE 1, LLC Kombinationstherapie von Beta-Blockern und nicht steroidalen antiinflammatorischen Antiphlogistika/Antirheumatika (NSAR)
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
EP2187892A1 (de) * 2007-09-17 2010-05-26 Bioneris AB Verfahren und mittel zur behandlung von kachexien
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2012135597A2 (en) 2011-03-30 2012-10-04 The Johns Hopkins University Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair
KR20130074808A (ko) * 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
EP2832357A1 (de) * 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selektive AT2-Rezeptoragonisten zur Verwendung bei der Behandlung von Kachexie
US20160334389A1 (en) * 2014-01-14 2016-11-17 Won Cheol Choi Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial
JP2016183174A (ja) * 2016-05-12 2016-10-20 ディフュージョン・ファーマシューティカルズ・エルエルシー 双極性トランスカロテノイド塩及びそれらの使用
EP3807898A1 (de) 2018-06-14 2021-04-21 AstraZeneca UK Limited Verfahren zur behandlung von bluthochdruck mit einer pharmazeutischen angiotensin-ii-rezeptorblockerzusammensetzung
DE202023100085U1 (de) 2023-01-09 2023-02-03 Sundararajan Gothandam Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655989B1 (fr) * 1989-12-20 1992-02-28 Adir Nouveaux derives d'amino-acides substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5049553A (en) * 1990-01-04 1991-09-17 E. R. Squibb & Sons, Inc. Method for preventing or treating symptoms resulting from closed head injuries employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2048699A1 (en) * 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
TW197945B (de) * 1990-11-27 1993-01-11 Hoechst Ag
FI905896A (fi) * 1990-11-29 1992-05-30 Valmet Paper Machinery Inc Formningsgapsarrangemang i en dubbelviraformare av en pappersmaskin.
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
GB9108811D0 (en) * 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
AU3968193A (en) 1992-03-26 1993-10-21 Gensia, Inc. In vivo peptide therapy
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
CA2140722A1 (en) * 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US5468757A (en) * 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
US5550118A (en) * 1994-01-31 1996-08-27 Eli Lilly And Company Polyhydronorharman synthase inhibitors
DE4410997A1 (de) * 1994-03-30 1995-10-26 Isis Pharma Gmbh Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen
DE4420102A1 (de) 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
TW356468B (en) * 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
CA2232663C (en) * 1995-10-06 2008-04-08 Novartis Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
WO1997021436A1 (en) * 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan
US6258032B1 (en) * 1997-01-29 2001-07-10 William M. Hammesfahr Method of diagnosis and treatment and related compositions and apparatus
US6420412B2 (en) 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
US20040122096A1 (en) * 1996-06-03 2004-06-24 Hoechst Aktiengesellschaft Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
CN1230178A (zh) 1996-09-10 1999-09-29 麦地诺克斯公司 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途
US6008221A (en) 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
BR9714047A (pt) * 1996-12-18 2000-05-09 Basf Ag Derivados de ácido carboxìlico, uso dos mesmos, combinação destes com um ou mais compostos ativos, preparação de drogas para a administração oral e parenteral, e, antagonista de receptor de endotelina
EP0855392A3 (de) * 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6197505B1 (en) * 1997-04-04 2001-03-06 Pyrosequencing Ab Methods for assessing cardiovascular status and compositions for use thereof
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Also Published As

Publication number Publication date
JP2009242426A (ja) 2009-10-22
DE69830069D1 (de) 2005-06-09
JP2003521437A (ja) 2003-07-15
ES2238770T5 (es) 2012-01-17
HUP0003982A3 (en) 2002-01-28
DE69830069T3 (de) 2012-02-09
US20140045907A1 (en) 2014-02-13
HU0900792D0 (en) 2010-03-01
PT1498124E (pt) 2007-10-16
UY25972A1 (es) 2001-08-27
EP1498124B1 (de) 2007-07-04
EP1559424A3 (de) 2009-11-11
DK1023067T3 (da) 2005-09-05
US20120178784A1 (en) 2012-07-12
KR20010031179A (ko) 2001-04-16
DK1023067T4 (da) 2011-12-12
EP1023067B1 (de) 2005-05-04
WO1999020260A3 (en) 2000-03-09
US7071183B2 (en) 2006-07-04
DE69830069T2 (de) 2006-01-19
EP1498124A2 (de) 2005-01-19
US8604070B2 (en) 2013-12-10
KR20010031177A (ko) 2001-04-16
US20020187939A1 (en) 2002-12-12
UY25971A1 (es) 2000-12-29
PL193215B1 (pl) 2007-01-31
NO20001979L (no) 2000-06-13
CA2306216A1 (en) 1999-04-29
CN1279606A (zh) 2001-01-10
CA2677910C (en) 2011-03-15
CA2306216C (en) 2011-06-07
ATE294579T1 (de) 2005-05-15
EP1776954A3 (de) 2009-11-11
EP1776954A2 (de) 2007-04-25
PL340838A1 (en) 2001-02-26
KR20050085966A (ko) 2005-08-29
PL197164B1 (pl) 2008-03-31
NO326231B1 (no) 2008-10-20
US20090069348A1 (en) 2009-03-12
DE69838042D1 (de) 2007-08-16
US20050192327A1 (en) 2005-09-01
DK1498124T3 (da) 2007-11-05
ES2238770T3 (es) 2005-09-01
EP1023067A2 (de) 2000-08-02
AP2000001796A0 (en) 2000-06-30
AU9453398A (en) 1999-05-10
US8003679B2 (en) 2011-08-23
CY1106813T1 (el) 2012-05-23
EP1559424A2 (de) 2005-08-03
EP1023067B9 (de) 2005-08-17
ES2287617T3 (es) 2007-12-16
CA2677910A1 (en) 1999-04-29
US20050192326A1 (en) 2005-09-01
AP1300A (en) 2004-09-08
EP1023067B2 (de) 2011-08-24
DE69838042T2 (de) 2008-03-06
WO1999020260A2 (en) 1999-04-29
NO20001979D0 (no) 2000-04-14
HUP0003982A1 (hu) 2001-11-28
KR100572080B1 (ko) 2006-04-17
JP5187991B2 (ja) 2013-04-24
KR100523112B1 (ko) 2005-10-19
PT1023067E (pt) 2005-09-30
AU742506B2 (en) 2002-01-03
US20060217429A1 (en) 2006-09-28
CN1123342C (zh) 2003-10-08
US7998953B2 (en) 2011-08-16
EP1498124A3 (de) 2005-08-17

Similar Documents

Publication Publication Date Title
ATE366110T1 (de) Verwendung von inhibitoren des renin-angiotensin systems
DE69913553D1 (de) Konfigurierung von systemeinheiten
FI973360A0 (fi) Uusia dipeptidisiä amidiineja trombiininestäjiksi
DE69717760D1 (de) Verwaltung des Softwaregebrauches von entfernten Rechnersystemen
FI980033A0 (fi) Solujen kiinnittymisen inhibiittoreita
ID19198A (id) Inhibitor metaloprotease heterosiklik
FI973282A (fi) Trombiinin inhibiittoreita
ID18416A (id) Inhibitor metaloprotease diheterosiklik
PT958287E (pt) Inibidores de sulfamida-metaloprotease
DK0858464T3 (da) Thrombin-inhibitorer
DE69828919D1 (de) Überprüfung des kathodischen Schutzes von erdverlegten Rohrleitungen
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE69728139D1 (de) Pyrrolopyrrolone als inhibitoren von neutrophiler elastase
FI974493A0 (fi) Arrangemang i samband med en hydraulisk slaganordning
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
DE69702751D1 (de) Dipeptidische benzamidine als kininogenasen-inhibitoren
DE69701947D1 (de) Aufhängung von Auspuffanlagen
DE69806750D1 (de) Amidinderivate als inhibitoren von no-synthase
DE69720957T2 (de) Ace-hemmer
ATE243857T1 (de) System zur zufuhr von toner
DE59811246D1 (de) System zur kontrolle der zugangsberechtigung
ID20094A (id) Alat pembersih
DE59809682D1 (de) Bearbeitungsanlage zur serienweisen Bearbeitung von Werkstücken
ID20123A (id) Alat pembersih
SE9704858D0 (sv) Detekteringar av förändringar i hydrauliska system

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1498124

Country of ref document: EP